The Life Sciences team advised Halda Therapeutics in its definitive agreement to be acquired by Johnson & Johnson for $3.05 billion in cash, subject to customary adjustments. The transaction includes Halda's lead program, HLD-0915, a first-in-class, oral RIPTAC" therapeutic in clinical development for metastatic castration-resistant prostate cancer, and is expected to advance Halda's broader pipeline of selective, proximity-based small molecule therapeutics.
Halda Therapeutics is a clinical-stage biotechnology company that has developed a proprietary RIPTAC" (Regulated Induced Proximity Targeting Chimeras) modality that works by a novel "hold and kill" mechanism for the precision treatment of cancer and other diseases. The lead RIPTAC programs are in clinical and pre-clinical development for major solid tumor types with additional RIPTAC therapeutic programs in the pipeline to treat serious diseases. Halda is led by a leadership team with deep expertise in biotechnology, drug discovery, platform innovation, and clinical development, and is in New Haven, CT. Halda was founded in 2019 and has been funded by Canaan Partners, Access Biotechnology, Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital and Taiho Ventures.
The Goodwin team was led by Joseph Theis, Robert Dzialo, Joseph Flynn, Dylan Miller, Daniela Sanchez, Jordan Kijewski; Arman Oruc, Selin Deldag; Elliot Silver, Kevin Walsh, Danielle Fong; Daniel Karelitz, Tyler Mayo; Sarah Bock, Eric Graffeo, Alexandra Watson-Tremellen; Timothy Holahan, Janelle Dempsey; Matthew Wetzel; Jonathan Ishee; Catherine McCarty; Sarah Solomon, Alexandra Faustin Haas, Jo-an Chen, Jacob Margolis; Omer Tene, Karl Dragosz; Jacob Osborn, Gozde Guckaya, Justin Shields; Elizabeth Mulkey, Krupa Zachariah; Brian Mukherjee, Amy Koss; and Nathan Brodeur.
For more information, please read the press release.